HC Wainwright & Co. Maintains Buy on ProQR Therapeutics, Lowers Price Target to $8
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsPrice Target
HC Wainwright & Co. analyst Ananda Ghosh maintains ProQR Therapeutics (NASDAQ:PRQR) with a Buy and lowers the price target from $12 to $8.
HC Wainwright & Co. analyst Ananda Ghosh maintains ProQR Therapeutics (NASDAQ:PRQR) with a Buy and lowers the price target from $12 to $8.